Who Exports Serum from India — 341 Suppliers Behind a $27.1M Market
India's serum export market is supplied by 341 active exporters who collectively shipped $27.1M across 15,000 shipments. BHARAT SERUMS AND VACCINES LIMITED leads with a 38.0% market share, followed by VINS BIOPRODUCTS LIMITED and PREMIUM SERUMS AND VACCINES PRIVATE LIMITED. The top 5 suppliers together control 73.3% of total export value, reflecting a concentrated market structure.
Top Serum Exporters from India — Ranked by Export Value
BHARAT SERUMS AND VACCINES LIMITED is the leading serum exporter from India, holding a 38.0% share of the $27.1M market across 15,000 shipments from 341 exporters. The top 5 suppliers — BHARAT SERUMS AND VACCINES LIMITED, VINS BIOPRODUCTS LIMITED, PREMIUM SERUMS AND VACCINES PRIVATE LIMITED, PREMIUM SERUMS VACCINES PVT LTD, ADVY CHEMICAL PRIVATE LIMITED — collectively control 73.3% of total export value, indicating a highly concentrated market. Individual shares are: BHARAT SERUMS AND VACCINES LIMITED (38.0%), VINS BIOPRODUCTS LIMITED (21.1%), PREMIUM SERUMS AND VACCINES PRIVATE LIMITED (5.3%), PREMIUM SERUMS VACCINES PVT LTD (4.7%), ADVY CHEMICAL PRIVATE LIMITED (4.2%).
Top Serum Exporters from India
Ranked by export value · 341 active suppliers · Indian Customs (DGFT) data
| # | Supplier & Formulations | Value | Ctry. | Share |
|---|---|---|---|---|
| 1 | BHARAT SERUMS AND VACCINES LIMITED EQUIRAB 1000IU/5ML [RABIES ANTISERUM - EQUINE]EQUIRAB 1000IU/5ML [RABIES ANTISERUM-EQUEQUIRAB 1000 IU/5ML [ RABIES ANTISERUM -EQUINE] | $10.3M | 29 | 38.0% |
| 2 | VINS BIOPRODUCTS LIMITED EQUIRAB 1000IU/5ML [RABIES ANTISERUM - EQUINE]EQUIRAB 1000IU/5ML [RABIES ANTISERUM-EQUEQUIRAB 1000 IU/5ML [ RABIES ANTISERUM -EQUINE] | $5.7M | 34 | 21.1% |
| 3 | PREMIUM SERUMS AND VACCINES PRIVATE LIMITED EQUIRAB 1000 IU/5ML [RABIES ANTISERUMEQUIRAB 1000 IU 5ML RABIES ANTISERUM EQUINESNAKE VENOM ANTISERUM IP LYOPHILISED | $1.4M | 21 | 5.3% |
| 4 | PREMIUM SERUMS VACCINES PVT LTD EQUIRAB 1000 IU/5ML [RABIES ANTISERUMEQUIRAB 1000 IU 5ML RABIES ANTISERUM EQUINESNAKE VENOM ANTISERUM IP LYOPHILISED | $1.3M | 5 | 4.7% |
| 5 | ADVY CHEMICAL PRIVATE LIMITED FETAL BOVINE SERUM, QUALIFIED, E.U.-APPRFETAL BOVINE SERUM STANDARD PARTFETAL BOVINE SERUM, STANDARD PAR | $1.1M | 15 | 4.2% |
| 6 | BIOLOGIX FETAL BOVINE SERUM, QUALIFIED, E.U.-APPRFETAL BOVINE SERUM STANDARD PARTFETAL BOVINE SERUM, STANDARD PAR | $926.0K | 1 | 3.4% |
| 7 | BIOMED EMPIRE FETAL BOVINE SERUM, QUALIFIED, E.U.-APPRFETAL BOVINE SERUM STANDARD PARTFETAL BOVINE SERUM, STANDARD PAR | $861.7K | 1 | 3.2% |
| 8 | HEMLIN CHEMICALS SURE FETAL BOVINE SERUM - RM10971EX-CELL 420 SERUM-FREE MEDIUM FOR INSECTSURE FETAL BOVINE SERUM | $670.2K | 1 | 2.5% |
| 9 | PREMIUM SERUMS VACCINES PRIVATE LIMITED EQUIRAB 1000 IU/5ML [RABIES ANTISERUMEQUIRAB 1000 IU 5ML RABIES ANTISERUM EQUINESNAKE VENOM ANTISERUM IP LYOPHILISED | $437.6K | 11 | 1.6% |
| 10 | PHAR & VIDE EQUIRAB 1000IU/5ML [RABIES ANTISERUM-EQUEQUIRAB 1000 IU/5ML [ RABIES ANTISERUM -EQUINE]EQUIRAB 1000IU/5ML [RABIES ANTISERUM - EQUINE] | $370.1K | 1 | 1.4% |
| 11 | BISISTA PHARMA PRIVATE LIMITED | $321.9K | 1 | 1.2% |
| 12 | PHARMA CHOICE LLP EQUIRAB 1000IU/5ML [RABIES ANTISERUM-EQUEQUIRAB 1000 IU/5ML [ RABIES ANTISERUM -EQUINE]EQUIRAB 1000IU/5ML [RABIES ANTISERUM - EQUINE] | $306.2K | 3 | 1.1% |
| 13 | VINS BIOPRODUCTS LTD EQUIRAB 1000IU/5ML [RABIES ANTISERUM - EQUINE]EQUIRAB 1000IU/5ML [RABIES ANTISERUM-EQUEQUIRAB 1000 IU/5ML [ RABIES ANTISERUM -EQUINE] | $260.6K | 6 | 1.0% |
| 14 | CLEARSYNTH LABS LIMITED SURE FETAL BOVINE SERUM - RM10971EX-CELL 420 SERUM-FREE MEDIUM FOR INSECTSURE FETAL BOVINE SERUM | $243.2K | 1 | 0.9% |
| 15 | HIMEDIA LABORATORIES PRIVATE LIMITED EQUIRAB 1000IU/5ML [RABIES ANTISERUM-EQUEQUIRAB 1000 IU/5ML [ RABIES ANTISERUM -EQUINE]EQUIRAB 1000IU/5ML [RABIES ANTISERUM - EQUINE] | $239.8K | 22 | 0.9% |
Related Analysis
Supplier Certification & Compliance Matrix
FDA, WHO-GMP, and EU GMP status for top Serum exporters
| Supplier | US FDA | WHO-GMP | EU GMP | ANDAs | Notes |
|---|---|---|---|---|---|
| Bharat Serums and Vaccines Limited | Not Listed | Yes | Yes | Not verified | Holds WHO-GMP and EU GMP certifications. |
| VINS Bioproducts Limited | Not Listed | Yes | No | Not verified | Listed as WHO-GMP certified. |
| Brilliant Bio Pharma Private Limited | Not Listed | Yes | No | Not verified | WHO-GMP certified manufacturer. |
TransData Nexus reviewed the regulatory standing of 3 leading Serum exporters from India. 0 hold US FDA facility approvals, 3 maintain WHO-GMP certification, and 1 are EU GMP compliant. For regulated markets (US, EU, Australia), prioritise suppliers with active FDA or EU GMP approvals. For semi-regulated markets (Africa, ASEAN, Latin America), WHO-GMP certification is the minimum recommended standard.
Certification status compiled from publicly available regulatory databases including FDA Orange Book, WHO Prequalification database, and EMA GMP registry. Buyers should independently verify compliance status with the relevant regulatory authority before placing orders.
TransData Nexus Research · Mar 2026
Manufacturing Hub Analysis — Vendor Proximity
India's pharmaceutical clusters relevant to Serum sourcing
1Hyderabad — Bulk Drug Capital
Hyderabad, often referred to as "Genome Valley," is a prominent hub for pharmaceutical manufacturing and biotech research in India. The city hosts major companies like Dr. Reddy’s Laboratories and Aurobindo Pharma, contributing significantly to the production of active pharmaceutical ingredients (APIs) and formulations. This robust infrastructure supports the development and export of various pharmaceutical products, including serums.
2Ahmedabad-Vadodara — Formulations Hub
The Ahmedabad-Vadodara corridor in Gujarat is a key center for pharmaceutical formulations. Companies such as Alembic Pharmaceuticals, Zydus Lifesciences, and Torrent Pharmaceuticals are headquartered here, focusing on the production of generic drugs and formulations. This region's emphasis on formulations complements the serum manufacturing sector, providing a comprehensive pharmaceutical ecosystem.
3Mumbai-Thane-Raigad — Export Gateway
The Mumbai-Thane-Raigad belt in Maharashtra serves as a critical export gateway for pharmaceutical products. Bharat Serums and Vaccines Limited (BSV), the leading serum exporter with $10.3 million in exports, is headquartered in Mumbai. The region's well-established port facilities and logistics infrastructure facilitate efficient international distribution of pharmaceutical products, including serums.
4Baddi-Nalagarh — Tax Incentive Zone
Baddi-Nalagarh in Himachal Pradesh is recognized as a tax incentive zone, attracting numerous pharmaceutical companies. The area offers benefits such as tax exemptions and subsidies, encouraging the establishment of manufacturing units. This has led to a concentration of pharmaceutical production, including serums, in the region.
5Sourcing Recommendations
- Engage with Leading Exporters: Prioritize partnerships with top serum exporters like Bharat Serums and Vaccines Limited (BSV) to ensure access to high-quality products and established supply chains.
- Leverage Established Clusters: Utilize the manufacturing capabilities of pharmaceutical clusters in Hyderabad, Ahmedabad-Vadodara, and Mumbai-Thane-Raigad to source serums efficiently.
- Consider Tax Incentive Zones: Explore sourcing opportunities from regions like Baddi-Nalagarh, which offer tax incentives and have a growing pharmaceutical manufacturing base.
- Monitor Export Destinations: Stay informed about key export markets such as the Philippines, Thailand, Algeria, Hong Kong, and Russia to align sourcing strategies with demand trends.
Recent M&A, Collaborations & Capacity Expansions
Industry developments among top Serum exporters from India
BHARAT SERUMS AND VACCINES LIMITED — Mankind Pharma to acquire 100% stake in Bharat Serums & Vaccines
On July 25, 2024, Mankind Pharma Limited announced a definitive agreement to acquire a 100% stake in Bharat Serums and Vaccines Limited (BSV) from Advent International for an enterprise value of approximately INR 13,630 crores. This strategic move positions Mankind Pharma as a market leader in the Indian women's health and fertility drug market, providing access to high-entry-barrier products in critical care with established complex R&D platforms. - IMPACT: The acquisition is expected to enhance Mankind Pharma's serum production capabilities, potentially increasing serum exports.
Impact: The acquisition is expected to enhance Mankind Pharma's serum production capabilities, potentially increasing serum exports.
BHARAT SERUMS AND VACCINES LIMITED — CCI approves Mankind Pharma's acquisition of Bharat Serums & Vaccines
On October 1, 2024, the Competition Commission of India (CCI) approved the proposed acquisition of Bharat Serums and Vaccines Limited by Mankind Pharma Limited. The transaction involves Mankind Pharma acquiring 100% shareholding of BSV, marking a significant consolidation in the pharmaceutical sector. - IMPACT: Regulatory approval facilitates the completion of the acquisition, likely leading to increased serum export activities under the consolidated entity.
Impact: Regulatory approval facilitates the completion of the acquisition, likely leading to increased serum export activities under the consolidated entity.
BHARAT SERUMS AND VACCINES LIMITED — Mankind Pharma completes acquisition of Bharat Serums & Vaccines
On October 23, 2024, Mankind Pharma Limited completed the acquisition of a 100% stake in Bharat Serums and Vaccines Limited for a purchase consideration of INR 13,768 crores. This strategic move positions Mankind Pharma as a market leader in the Indian women's health and fertility drug market, providing access to high-entry-barrier products in critical care with established complex R&D platforms. - IMPACT: The completion of the acquisition is expected to enhance Mankind Pharma's serum production capabilities, potentially increasing serum exports.
Impact: The completion of the acquisition is expected to enhance Mankind Pharma's serum production capabilities, potentially increasing serum exports.
Common Questions — Serum Suppliers from India
Answers based on Indian Customs (DGFT) shipment records compiled by TransData Nexus
Q Which serum supplier from India is the most reliable for bulk orders?
Based on shipment frequency and export consistency, BHARAT SERUMS AND VACCINES LIMITED leads with 131 recorded shipments worth $10.3M. VINS BIOPRODUCTS LIMITED (132 shipments) and PREMIUM SERUMS AND VACCINES PRIVATE LIMITED (31 shipments) are also established high-volume exporters.
Q How many serum manufacturers are there in India?
India has 341 active serum exporters with a combined export market of $27.1M across 15,000 shipments to 122 countries. The top 5 suppliers hold 73.3% of total export value.
Q What certifications should I verify?
Verify: WHO-GMP certification (most markets), US FDA approval (United States), EU GMP certificate (EU/EEA), and Free Sale Certificate from CDSCO. Always request a Certificate of Analysis (CoA) and Certificate of Origin (CoO).
Q What is the typical price range for serum from India?
Average FOB unit price: $36.03 per unit, ranging from $0.01 to $9389.80. Average shipment value: $1.8K.
Official References & Regulatory Resources
- CDSCO India
- Pharmexcil
- IBEF — India Pharma Industry
- Ministry of Commerce — Pharma Exports
- India Trade Statistics (DGFT)
Verify manufacturer licensing and export certifications with the official agencies above.
Research Methodology & Data Transparency
Suresh Sormare
Verified AuthorPharmaceutical Export-Import Analyst & Trade Intelligence Expert
Suresh Sormare is a pharmaceutical export-import analyst with deep expertise in Indian Customs (DGFT) data, HS code classification, and global pharmaceutical supply chains. His analysis covers 10M+ shipment records across 150+ countries and is used by manufacturers, procurement agencies, and trade consultants worldwide. Suresh specializes in identifying verified suppliers and buyers from customs records, mapping bilateral pharmaceutical trade corridors, analyzing tariff structures and regulatory frameworks across 170+ destination markets, and benchmarking competitive positioning for finished pharmaceutical formulations. His methodology combines granular customs transaction data with regulatory intelligence from FDA, EMA, WHO, CDSCO, and 40+ national drug authorities to deliver actionable trade insights for the pharmaceutical formulations sector.
linkedin.com/in/sureshsormarePrimary Data Source
All trade data is sourced from Indian Customs (DGFT) official shipping bill records — the authoritative government database for India's pharmaceutical trade. Each verified record contains exporter name, consignee (buyer) name, detailed product description, quantity, declared FOB value (USD), port of loading, destination country, and shipment date.
Analysis Methodology
- 1.Supplier Ranking: 341 verified Indian exporters of Serum ranked by capped export value from DGFT shipping bill records.
- 2.Export Value Analysis: Total export value aggregated from 15,000 individual shipping bill records. Values are FOB in USD.
- 3.Statistical Normalization: Shipment values are statistically normalized to ensure accurate market share representation.
- 4.Market Concentration: Supplier market share and geographic reach analyzed across 122 destination countries.
Government-Sourced Data
Official DGFT customs records
Transparent Methodology
Calculations fully disclosed above
15,000 Verified Shipments
341 exporters tracked
Expert-Reviewed
By pharmaceutical trade specialists